NR4A1 and cancer: Anthracycline regimen recipients were statistically significantly younger, had more positive nodes, were more likely to have hormone receptor (HR)-negative cancer, a higher histologic grade, and to have had a mastectomy, compared to those treated with the non-anthracycline regimen.